Last 14 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -6.05 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 1.39 | 2.56 | 1.95 | 1.35 | 1.83 | 0.60 | 0.98 | 1.91 | 2.34 | 2.08 | — | — | — | — | — |
| — | +327.2% | +99.6% | -29.3% | -21.9% | -71.2% | — | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | 1.07 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -26.1% | -6.2% | -5.7% | -6.9% | -7.3% | -9.0% | -8.4% | -7.1% | -4.8% | -12.7% | — | — | — | -12.3% | -19.1% |
| — | +31.3% | +32.3% | +3.8% | -51.5% | +29.1% | — | — | — | -3.4% | — | — | — | — | — | |
| ROA | -24.5% | -5.9% | -5.4% | -6.5% | -6.8% | -8.4% | -7.8% | -6.8% | -4.7% | -5.2% | -6.6% | -5.8% | -4.5% | — | -14.8% |
| — | +29.6% | +30.9% | +4.5% | -45.8% | -61.1% | -17.3% | -17.8% | -4.4% | — | +55.3% | — | — | — | — | |
| ROIC | -27.1% | -5.6% | -5.9% | -7.6% | -7.5% | -8.3% | -7.7% | 36.1% | -6.3% | -6.8% | -7.1% | -45.1% | -135.0% | -6.1% | — |
| — | +32.5% | +24.0% | -121.1% | -19.4% | -22.0% | -9.8% | +180.0% | +95.4% | -11.4% | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.00 | 0.00 | — | — | — | — | 0.15 |
| — | -18.2% | -14.4% | +0.0% | +947.4% | +1122.2% | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | 0.07 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 27.50 | 37.17 | 38.00 | 27.50 | 29.07 | 24.51 | 21.47 | 20.69 | 37.06 | 58.92 | 19.20 | 23.29 | 18.50 | — | 6.41 |
| — | +51.6% | +77.0% | +32.9% | -21.5% | -58.4% | +11.8% | -11.1% | +100.4% | — | +199.6% | — | — | — | — | |
| Quick Ratio | 27.50 | 37.17 | 38.00 | 27.50 | 29.07 | 24.51 | 21.47 | 20.69 | 37.06 | 58.92 | 19.20 | 23.29 | 18.50 | — | 6.41 |
| — | +51.6% | +77.0% | +32.9% | -21.5% | -58.4% | +11.8% | -11.1% | +100.4% | — | +199.6% | — | — | — | — | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | -51.43 | -73.38 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 14 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CTNM stock.
Contineum Therapeutics, Inc.'s current P/E is -6.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Contineum Therapeutics, Inc.'s business trajectory between earnings reports.